Wolf Herman Fridman;Saroop Singh Matharu;David Bebbington;Julian M. C. Golec;David J. Lauffer;Michael D. Mullican;David J. Livingston;Yong Gu;Mark James Batchelor;Roger John Gillespie;Guy W. Bemis;Mar
发明人:
Mark James Batchelor,David Bebbington,Guy W. Bemis,Wolf Herman Fridman,Roger John Gillespie,Julian M. C. Golec,Yong Gu,David J. Lauffer,David J. Livingston,Saroop Singh Matharu,Michael D. Mullican,Mar
申请号：
US12786221
公开号：
US08119631B2
申请日:
2010.05.24
申请国别(地区):
US
年份:
2012
代理人:
摘要：
The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against IL-1-, apoptosis-, IGIF-, and IFN-γ-mediated diseases, inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, degenerative diseases, and necrotic diseases. This invention also relates to methods for inhibiting ICE activity, for treating interleukin-1-, apoptosis-, IGIF- and IFN-γ-mediated diseases and decreasing IGIF and IFN-γ production using the compounds and compositions of this invention. This invention also relates to methods for preparing N-acylamino compounds.
